Trial Profile
An Open-Label, Multicenter, Dose Escalation and Expansion Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cibisatamab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 10 Feb 2020 Status changed from active, no longer recruiting to completed.
- 04 Dec 2019 Planned End Date changed from 13 Dec 2019 to 29 Jan 2020.
- 04 Dec 2019 Planned primary completion date changed from 13 Dec 2019 to 29 Jan 2020.